Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Segments and Strategic Initiatives
JNJ logo

Johnson & Johnson Hits $94.2 Billion In Sales Driven By 22% Oncology Growth

JNJ10-KFiling Date: 2/11/2026
Johnson & Johnson
Description

What this story covers

Johnson & Johnson’s 2025 10-K reveals a strategic pivot toward high-growth oncology and MedTech. Despite $94.2 billion in sales, the company faces significant biosimilar competition for STELARA and ongoing multi-billion dollar legal contingencies regarding talc and opioid litigation.

Story snapshot

CompanyJohnson & Johnson
TickerJNJ
VariantStandard detailed
Duration11:43
Filing type10-K
PeriodAnnual 2025
IndustryHealthcare & Pharmaceuticals
Accession0000200406-26-000016
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in